Predictors of long-term survival in patients with DLBCL/HGBCL following autoSCT

Clinical features and long-term outcomes of autoSCT & alloSCT in R/R DLBCL between 1990 and 2019Подробнее

LY.12 & CORAL: long-term survival in relapsed DLBCL after ASCTПодробнее

Outcomes of patients with DLBCL who relapse early following R-ICE chemoimmunotherapyПодробнее

Loncastuximab tesirine: long-term survival data from LOTIS-2 & insights into the LOTIS-7 trialПодробнее

Using AI to predict the outcomes of patients with R/R DLBCL treated with tisagenlecleucelПодробнее

Overall survival in patients with cHL who progress after autoSCT in the era of novel agentsПодробнее

Real-world long-term outcomes of patients with LBCL treated with axi-celПодробнее

Outcomes of patients with DLBCL following ASCT and/or CAR-TПодробнее

PET2-assoicated outcomes in patients with DLBCLПодробнее

Long-term follow-up of tafasitamab and lenalidomide in R/R DLBCLПодробнее

Autologous transplantation in DLBCL and unmet needsПодробнее

How can predicting survival in patients with relapsed DLBCL improve treatment decisions?Подробнее

Quality of Life at Diagnosis May Predict Survival for Patients With Aggressive LymphomaПодробнее

Association of interim PET2 response with outcomes in patients with DLBCLПодробнее

Analysis of long-term survival in a large APL patient cohort: a Harmony Alliance studyПодробнее

Transplant or CAR T-cell Therapy for Lymphoma? How to Make the ChoiceПодробнее

CAR-T therapy versus autoSCT in DLBCLПодробнее

Improving survival outcomes and optimizing CAR-T therapy in patients with DLBCLПодробнее

Debate: Relapsed 60 y/o Follicular lymphoma patient after upfront R-CHOP - SCTПодробнее